Gustavo Monnerat, Deputy Editor at The Lancet, shared a post on LinkedIn:
“Nature Biotechnology just published its editorial on the most impactful advances in biotechnology in 2025.
Among them, these are the ones I found most compelling:
1) In vivo cellular therapies
Shifting away from ex vivo manufacturing toward in vivo reprogramming of immune cells, exemplified by targeted lipid nanoparticle delivery of mRNA to specific T-cell subsets for CAR-T–like therapies. This approach can reduce manufacturing complexity, cost, and reliance on chemotherapy.
2) Personalized cancer vaccines
Early-phase clinical trials showed promising results for neoantigen-targeted cancer vaccines, reinforcing their potential as a durable therapeutic strategy rather than a transient trend.
3) Post-animal preclinical models
Tumor-on-chip and organ-on-chip technologies gained prominence, aligning with regulatory moves (including FDA initiatives) to reduce animal testing while offering scalable.
4) Next-generation genome engineering
Novel systems such as bridge recombinases and CRISPR-coupled retrotransposons enable precise, large-scale, and scar-free DNA insertions, excisions, and inversions, expanding the scope of genome editing.
Which advance do you think will have the greatest clinical impact?”
More posts featuring Gustavo Monnerat.